{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:07:46Z","timestamp":1771546066240,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.hroo.2025.11.019","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T20:37:34Z","timestamp":1767386254000},"page":"264-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-9906","authenticated-orcid":false,"given":"Jay W.","family":"Mason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne J.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary T.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boaz","family":"Mendzelevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie H.","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Badilini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Gillings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome B.","family":"Riebman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2025.11.019_bib1","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.1016\/j.hrthm.2025.03.1892","article-title":"PO-07-195 Safety and efficacy of HBI-3000, an investigational multichannel blocker for patients with non-permanent atrial fibrillation: initial clinical findings","volume":"22","author":"Roy","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2025.11.019_bib2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/aps.2012.119","article-title":"Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent","volume":"33","author":"Bai","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.hroo.2025.11.019_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/fcp.12242","article-title":"Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects","volume":"31","author":"Chen","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.hroo.2025.11.019_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2018.12.009","article-title":"Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound","volume":"844","author":"Chen","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hroo.2025.11.019_bib5","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/bmc.3681","article-title":"Determination of the novel antiarrhythmic drug sulcardine sulfate in human plasma by liquid chromatography tandem mass spectrometry and its application in a clinical pharmacokinetic study","volume":"30","author":"Jia","year":"2016","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.hroo.2025.11.019_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13318-016-0360-3","article-title":"Oral bioavailability and mass balance studies of a novel anti-arrhythmic agent sulcardine sulfate in Sprague-Dawley rats and beagle dogs","volume":"42","author":"Lu","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.hroo.2025.11.019_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13318-016-0370-1","article-title":"Multiple dose pharmacokinetics and safety of sulcardine sulfate in healthy Chinese male subjects: an open-label Phase I clinical study","volume":"42","author":"Wang","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.hroo.2025.11.019_bib8","first-page":"84","article-title":"Clinical observation on changrolin, an antiarrhythmic drug","volume":"58","year":"1978","journal-title":"Natl Med J Chin"},{"key":"10.1016\/j.hroo.2025.11.019_bib9","first-page":"1220","article-title":"Studies on a new antiarrhythmic drug changrolin-4-(3',5'-bis [(N-pyrrolidinyl) methyl]-4'-hydroxyanilino)-quinazoline","volume":"22","author":"Li","year":"1979","journal-title":"Sci Sin"},{"key":"10.1016\/j.hroo.2025.11.019_bib10","first-page":"564","article-title":"[Studies on drugs for coronary diseases. II. Synthesis of compounds related to changrolin as potential antiarrhythmic drugs (author\u2019s transl)]","volume":"16","author":"Sun","year":"1981","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.hroo.2025.11.019_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FJC.0b013e3181ffe8b3","article-title":"Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes","volume":"57","author":"Guo","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hroo.2025.11.019_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1074248413485433","article-title":"HBI-3000 prevents secondary sudden cardiac death","volume":"18","author":"Lee","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hroo.2025.11.019_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.hroo.2025.11.019_bib14","first-page":"A4136839","article-title":"HBI-3000: pharmacological conversion of atrial fibrillation with unique defense against excessive QT interval prolongation","volume":"150","author":"Mason","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2025.11.019_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1542-474X.2009.00287.x","article-title":"Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients","volume":"14","author":"Schwaab","year":"2009","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.hroo.2025.11.019_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(91)90435-N","article-title":"Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide","volume":"67","author":"Donovan","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2025.11.019_bib17","first-page":"1080","article-title":"Intravenous amiodarone in treatment of recent-onset atrial fibrillation","volume":"28","author":"Lip","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2025.11.019_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9149(96)00565-6","article-title":"Efficacy of ibutilide for termination of atrial fibrillation and flutter","volume":"78","author":"Ellenbogen","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2025.11.019_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003495-199958060-00007","article-title":"Dofetilide: a review of its use in atrial fibrillation and atrial flutter","volume":"58","author":"McClellan","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.hroo.2025.11.019_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphar.2020.00413","article-title":"Late sodium current inhibitors as potential antiarrhythmic agents","volume":"11","author":"Horv\u00e1th","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hroo.2025.11.019_bib21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.hrthm.2008.09.008","article-title":"Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine","volume":"5","author":"Wu","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2025.11.019_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2004.09.069","article-title":"Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil","volume":"45","author":"Aiba","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2025.11.019_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1091581818813601","article-title":"A proof-of-concept evaluation of JTPc and Tp-Tec as proarrhythmia biomarkers in preclinical species: a retrospective analysis by an HESI-sponsored consortium","volume":"38","author":"Boulay","year":"2019","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.hroo.2025.11.019_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501825005653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501825005653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:20:59Z","timestamp":1771543259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501825005653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666501825005653"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2025.11.019","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}